Compare InspireMD, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 69 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.97
-72.06%
1.07
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Sep 2025)
Net Profit:
-13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.82%
0%
-22.82%
6 Months
-38.58%
0%
-38.58%
1 Year
-37.64%
0%
-37.64%
2 Years
-42.05%
0%
-42.05%
3 Years
32.26%
0%
32.26%
4 Years
-37.4%
0%
-37.4%
5 Years
-83.74%
0%
-83.74%
InspireMD, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.46%
EBIT Growth (5y)
-222.13%
EBIT to Interest (avg)
-21.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.18
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.08%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.70
EV to EBIT
-1.36
EV to EBITDA
-1.37
EV to Capital Employed
17.40
EV to Sales
7.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1276.31%
ROE (Latest)
-127.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 2 Schemes (0.16%)
Foreign Institutions
Held by 8 Foreign Institutions (10.39%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
2.50
1.80
38.89%
Operating Profit (PBDIT) excl Other Income
-12.90
-12.90
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.70
-13.20
3.79%
Operating Profit Margin (Excl OI)
-5,172.80%
-7,322.30%
214.95%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 38.89% vs 20.00% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 3.79% vs -17.86% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
7.00
6.20
12.90%
Operating Profit (PBDIT) excl Other Income
-32.90
-20.70
-58.94%
Interest
0.00
0.00
Exceptional Items
-0.30
-0.30
Consolidate Net Profit
-32.00
-19.90
-60.80%
Operating Profit Margin (Excl OI)
-4,738.20%
-3,366.20%
-137.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 12.90% vs 19.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -60.80% vs -7.57% in Dec 2023
About InspireMD, Inc. 
InspireMD, Inc.
Pharmaceuticals & Biotechnology
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Company Coordinates 
Company Details
4 Menorat Hamaor St. , TEL AVIV-YAFO MA : 6744832
Registrar Details






